This latest commitment brings the British pharmaceutical company’s total investment at the site to $886 million
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
Furthering?U.S.-based?pharmaceutical?capacity?to?produce?critical respiratory medicines?
The platform is being introduced to expand access to treatments for people living with chronic conditions
Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
Includes new $1.2 billion investment in manufacturing facilities, AI and advanced digital technologies, creating hundreds of highly skilled U.S. jobs
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
Subscribe To Our Newsletter & Stay Updated